CL2013001591A1 - Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. - Google Patents
Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.Info
- Publication number
- CL2013001591A1 CL2013001591A1 CL2013001591A CL2013001591A CL2013001591A1 CL 2013001591 A1 CL2013001591 A1 CL 2013001591A1 CL 2013001591 A CL2013001591 A CL 2013001591A CL 2013001591 A CL2013001591 A CL 2013001591A CL 2013001591 A1 CL2013001591 A1 CL 2013001591A1
- Authority
- CL
- Chile
- Prior art keywords
- triazolopyridine
- schizophrenia
- anxiety
- prophylaxis
- diseases
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title 1
- 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10194014 | 2010-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001591A1 true CL2013001591A1 (es) | 2013-12-27 |
Family
ID=45099086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001591A CL2013001591A1 (es) | 2010-12-07 | 2013-06-04 | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8349824B2 (es) |
| EP (1) | EP2649070B1 (es) |
| JP (1) | JP5932828B2 (es) |
| KR (1) | KR20130128426A (es) |
| CN (1) | CN103237803B (es) |
| AR (1) | AR084152A1 (es) |
| AU (1) | AU2011340685A1 (es) |
| BR (1) | BR112013013912A2 (es) |
| CA (1) | CA2816829C (es) |
| CL (1) | CL2013001591A1 (es) |
| CO (1) | CO6741154A2 (es) |
| CR (1) | CR20130239A (es) |
| CY (1) | CY1115863T1 (es) |
| DK (1) | DK2649070T3 (es) |
| EA (1) | EA022607B1 (es) |
| EC (1) | ECSP13012667A (es) |
| ES (1) | ES2520647T3 (es) |
| HR (1) | HRP20141200T1 (es) |
| IL (1) | IL225969A0 (es) |
| MA (1) | MA35086B1 (es) |
| MX (1) | MX2013006054A (es) |
| PE (1) | PE20140226A1 (es) |
| PH (1) | PH12013500942A1 (es) |
| PL (1) | PL2649070T3 (es) |
| PT (1) | PT2649070E (es) |
| RS (1) | RS53677B1 (es) |
| SG (1) | SG190305A1 (es) |
| SI (1) | SI2649070T1 (es) |
| UA (1) | UA109037C2 (es) |
| WO (1) | WO2012076430A1 (es) |
| ZA (1) | ZA201303811B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043520A1 (en) * | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| RU2620379C2 (ru) | 2012-02-09 | 2017-05-25 | Ф.Хоффманн-Ля Рош Аг | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 2-ФЕНИЛ[1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИНА |
| MX2015009377A (es) * | 2013-01-31 | 2015-10-09 | Hoffmann La Roche | Compuestos radiomarcados. |
| MX2015010971A (es) | 2013-02-27 | 2015-10-26 | Mochida Pharm Co Ltd | Derivado novedoso de pirazol. |
| MY169128A (en) | 2013-04-30 | 2019-02-18 | Hoffmann La Roche | Pd-catalyzed coupling of pyrazole amides |
| BR112015029899B1 (pt) * | 2013-05-31 | 2020-07-21 | Nissan Chemical Corporation | composto de amida heterocíclica e sal do mesmo da formula (1), produto quimico agrícola e herbicida obtido |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| EP3176168A4 (en) | 2014-07-30 | 2018-05-02 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
| EP3176167A4 (en) | 2014-07-30 | 2018-03-28 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| BR112022024751A2 (pt) * | 2020-06-05 | 2023-03-07 | Noema Pharma Ag | Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de tourette |
| AU2022214289A1 (en) | 2021-01-28 | 2023-08-10 | Noema Pharma Ag | Methods for the treatment of childhood-onset fluency disorder |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007508241A (ja) | 2003-07-31 | 2007-04-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pde10a阻害剤を用いる糖尿病および関連障害の処置方法 |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/es active Active
- 2011-12-05 EA EA201390799A patent/EA022607B1/ru not_active IP Right Cessation
- 2011-12-05 AR ARP110104533A patent/AR084152A1/es unknown
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/en active Active
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/zh active Active
- 2011-12-05 UA UAA201308329A patent/UA109037C2/uk unknown
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/es active IP Right Grant
- 2011-12-05 PH PH1/2013/500942A patent/PH12013500942A1/en unknown
- 2011-12-05 PT PT117915439T patent/PT2649070E/pt unknown
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/ko not_active Ceased
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/en not_active Ceased
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/ja active Active
- 2011-12-05 SI SI201130309T patent/SI2649070T1/sl unknown
- 2011-12-05 HR HRP20141200AT patent/HRP20141200T1/hr unknown
- 2011-12-05 CA CA2816829A patent/CA2816829C/en active Active
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/pt not_active Application Discontinuation
- 2011-12-05 RS RS20140574A patent/RS53677B1/sr unknown
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/es not_active Application Discontinuation
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/da active
- 2011-12-05 PL PL11791543T patent/PL2649070T3/pl unknown
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
-
2013
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-04-25 CO CO13105814A patent/CO6741154A2/es active IP Right Grant
- 2013-05-22 CR CR20130239A patent/CR20130239A/es unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/es unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/es unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/fr unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| MX349796B (es) | Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10. | |
| CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| CL2012002771A1 (es) | Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo. | |
| CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
| CL2014000450A1 (es) | Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros. | |
| LT3216448T (lt) | Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sisteminio poveikio veikliuosius agentus, būdai ir jų panaudojimas | |
| CL2014002847A1 (es) | Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. | |
| CL2011001299A1 (es) | Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| CO6791606A2 (es) | Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| LT3632919T (lt) | Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| CL2013002177A1 (es) | Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| CL2008000307A1 (es) | Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc. | |
| EP2841068B8 (en) | Crhr1 antagonists for use in the treatment of patients having crh overactivity | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. |